A Phase 4 interventional study of Etanercept and OCT in Psoriasis, Psoriatic Arthritis and Psoriatic Nail, sponsored by OptiSkin Medical. Status unknown at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-06.
Sponsored by OptiSkin Medical · Phase 4, Interventional, and Treatment
OptiSkin is now enrolling a new study to monitor nail changes in patients with nail psoriasis treated with Enbrel® (etanercept) with optical coherence tomography (OCT).
Psoriasis often affects the fingernails, making them yellow, brittle, painful and prone to infections. These symptoms can be difficult to manage, so OptiSkin is now enrolling a new study to monitor nail changes in patients with nail psoriasis treated with Enbrel® (etanercept) with optical coherence tomography (OCT).
OCT is being studied as a way to better diagnosis psoriatic nail disease, monitor response to therapy, and identify changes even before they become apparent, potentially leading to earlier treatment or prevention of future psoriatic arthritis.
Study-related care and medication are provided at no cost, and reimbursement for reasonable local transportation may be available to qualified individuals.
3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.
This study's planned enrollment of 10 is below the median of 90 across 2,377 interventional studies indexed under Arthritis.
Browse Arthritis studies →OptiSkin Medical is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
50mg etanercept subcutaneously twice weekly for 3 months, followed by once weekly for another 3 months for a total duration of 6 months or 24 weeks.
Drug: Etanercept · Device: OCT
TNF-alpha inhibitors improve nail psoriasis.
Also known as: Enbrel
Optical Coherence Tomography is a noninvasive imaging device that can be used to monitor nail disease severity.
Also known as: Optical Coherence Tomography
NAPSI
Nail Psoriasis Severity Index (NAPSI) score is an established measure of nail disease ranging from 0-100. A higher score indicates more severe nails psoriasis.
Time frame: Baseline to 24 weeks
OCT (clinical)
Optical Coherence Tomography is noninvasive imaging that can be used to monitor nail disease severity.
Time frame: Baseline to 24 weeks
OCT (sub-clinical)
Optical Coherence Tomography is noninvasive imaging that will be used to detect subclinical changes in otherwise healthy-appearing nails.
Time frame: Baseline to 24 weeks
Dermoscopy
Dermoscopy allows for the examination of the skin using skin surface microscopy.
Time frame: Baseline to 24 weeks
Plan to share: No
This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
OptiSkin Medical